Torgerson D J, Reid D M
National Primary Care Research and Development Centre, University of York, Heslington, England.
Pharmacoeconomics. 1997 Feb;11(2):126-38. doi: 10.2165/00019053-199711020-00003.
A systematic review of all published economic evaluations of treatments for the prevention of osteoporosis since 1980 was undertaken. 21 published studies were identified. The majority of the studies were set in the context of the US healthcare system. Non-US studies were heavily influenced by the methodologies of 1 US research group. All studies published before 1990 only considered the use of hormone replacement therapy (HRT) at the menopause for osteoporosis prevention. Since 1990 a number of studies have looked at other therapies as well as HRT in older women. All studies that have made a direct comparison between using HRT at the menopause with HRT in older women have suggested that it is more cost effective to initiate therapy in older non-perimenopausal women. However, there is a paucity of evidence from randomised controlled trials on which to base assumptions on costs and effectiveness. Large randomised trails with hip fracture as the main outcome measure are required to answer key economic and clinical questions.
对自1980年以来发表的所有关于预防骨质疏松症治疗的经济评估进行了系统综述。共识别出21项已发表的研究。大多数研究是在美国医疗保健系统的背景下进行的。非美国的研究受到1个美国研究小组方法的严重影响。1990年以前发表的所有研究仅考虑在绝经时使用激素替代疗法(HRT)预防骨质疏松症。自1990年以来,一些研究也关注了老年女性的其他疗法以及HRT。所有直接比较绝经时使用HRT与老年女性使用HRT的研究都表明,在非围绝经期老年女性中开始治疗更具成本效益。然而,缺乏来自随机对照试验的证据来作为成本和有效性假设的基础。需要以髋部骨折为主要结局指标的大型随机试验来回答关键的经济和临床问题。